Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Eva Hanze"'
Autor:
Anu Shilpa Krishnatry, Eva Hanze, Tim Bergsma, Arindam Dhar, Marita Prohn, Geraldine Ferron‐Brady
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 5, Pp 556-568 (2022)
Abstract Molibresib (GSK525762) is an investigational orally bioavailable small‐molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. In the first‐time‐in‐human BET115521 study of molibresi
Externí odkaz:
https://doaj.org/article/2b0ccaef881e4460bb633401de97eee9
Autor:
Yaping Tu, Eva Hanze, Fengying Zhu, Maxime Lagraauw, Callum Sloss, Michael Method, Brooke Esteves, Eric Westin, Anna Berkenblit
Aims: Mirvetuximab soravtansine is the first-in-class antibody-drug conjugate approved in November 2022 for the treatment of folate receptor-α positive ovarian cancer. The aim of this study was to develop a population pharmacokinetic (PK) model to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb888b928c21bf771759f5cf6fee7a92
https://doi.org/10.22541/au.167533208.87309627/v1
https://doi.org/10.22541/au.167533208.87309627/v1
Autor:
Anu Shilpa Krishnatry, Arindam Dhar, Marita Prohn, Tim Bergsma, Geraldine Ferron-Brady, Eva Hanze
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:556-568
Molibresib (GSK525762) is an investigational orally bioavailable small-molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. In the first-time-in-human BET115521 study of molibresib in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7be2d8c010fec6ccc7eee020e3117ce
https://doi.org/10.1002/psp4.12724
https://doi.org/10.1002/psp4.12724
Autor:
Jeffrey Wald, Anja Henningsson, Eva Hanze, Ethan Hoffmann, Haihong Li, Helen Colquhoun, Kristina M. Deligiannidis
Publikováno v:
Clinical pharmacokinetics. 61(9)
Women with postpartum depression (PPD) may expose their infants to antidepressants via breast milk. Brexanolone is the only FDA-approved antidepressant specifically indicated for the treatment of PPD. This open-label, phase Ib study of healthy lactat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a225503eb750dfcaff724f4c06dad4
https://pubmed.ncbi.nlm.nih.gov/35869362
https://pubmed.ncbi.nlm.nih.gov/35869362
Publikováno v:
British journal of clinical pharmacology. 88(9)
Develop a population pharmacokinetic (PopPK) model to characterise the pharmacokinetics (PK) of anti-programmed cell death protein-1 (PD-1) antibody dostarlimab, identify covariates of clinical relevance, and investigate efficacy/safety exposure-resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67623fd9b7b3cfa9a93e1ea81bc14708
https://pubmed.ncbi.nlm.nih.gov/35357027
https://pubmed.ncbi.nlm.nih.gov/35357027
Autor:
Ayman Grada, James Q. Del Rosso, Emmy Graber, Christopher G. Bunick, Linda Stein Gold, Angela Y. Moore, Hilary Baldwin, Zaidal Obagi, Giovanni Damiani, Timothy Carrothers, Brian McNamee, Eva Hanze
Publikováno v:
Dermatologic Therapy. 35
Tetracycline-class antibiotics are frequently prescribed by dermatologists, commonly for acne vulgaris. Gastrointestinal absorption of first and second-generation tetracycline-class antibiotics, including doxycycline and minocycline, may be reduced b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94eca4176308ba2d24d9c827a5febddd
https://doi.org/10.1111/dth.15275
https://doi.org/10.1111/dth.15275
Autor:
Ibrahim Ince, Klaas Prins, Stefan Willmann, Gabriele Sutter, Eva Hanze, Farrah Sadre‐Marandi, Heino Stass, Dirk Garmann
Publikováno v:
Journal of clinical pharmacologyReferences. 62(10)
Nifurtimox (LAMPIT) has been used for decades for the treatment of Chagas disease, a chronic and potentially life-threatening disease caused by the parasite Trypanosoma cruzi. The pharmacokinetic (PK) information on nifurtimox in humans derived from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc1fa5ba8b6ced484a12ced21e6d0143
https://pubmed.ncbi.nlm.nih.gov/35460577
https://pubmed.ncbi.nlm.nih.gov/35460577
Publikováno v:
The Journal of Clinical Pharmacology. 54:1337-1346
Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor which has been evaluated as a potential treatment for rheumatoid arthritis (RA). Treatment with fostamatinib has been associated with an increase in blood pressure (BP). In this work, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e0123570bc8da8b9748d80265cfad0b
https://doi.org/10.1002/jcph.341
https://doi.org/10.1002/jcph.341
Publikováno v:
Pharmaceutical Research. 26:2174-2185
To investigate the use of adaptive transformations to assess the parameter distributions in population modeling. The logit, box-cox, and heavy tailed transformations were investigated. Each one was used in conjunction with the standard (exponential)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4854fdbcaa25a99c8c3ecfacba2274dc
https://doi.org/10.1007/s11095-009-9931-1
https://doi.org/10.1007/s11095-009-9931-1
Autor:
Emma, Boström, Fredrik, Öhrn, Eva, Hanze, Marie, Sandström, Paul, Martin, Ulrika, Wählby-Hamrén
Publikováno v:
Journal of clinical pharmacology. 54(12)
Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor which has been evaluated as a potential treatment for rheumatoid arthritis (RA). Treatment with fostamatinib has been associated with an increase in blood pressure (BP). In this work, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec79f68fd68710f3fdb449dc54d1b40f
https://pubmed.ncbi.nlm.nih.gov/24895144
https://pubmed.ncbi.nlm.nih.gov/24895144